Professor, Urology, University of Texas Southwestern Medical Center, Southwestern Medical School
Urology
Dr. Arthur I. Sagalowsky, MD
|
|
Give Review
Doctor Arthur I. Sagalowsky, MD is an expert in the field of Urology. He went to medical school at Indiana University School of Medicine. Indiana University School of Medicine is ranked 45 in research and 47 in primary care medicine He over the years received 6 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Super Doctor", "Whos Who in Medicine and Healthcare" and "Fellow (FACS)". Arthur I. Sagalowsky is also published. He has 92 publications published. The lastest publication: "The Utility of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance.' Arthur Sagalowsky is registered with Medicare.
Publications
- Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?
- The Utility of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance.
- Association of distance to treatment facility on quality and survival outcomes after radical cystectomy for Bladder cancer.
- Stereotactic Radiation Therapy of Renal Cancer Inferior Vena Cava Tumor Thrombus.
- Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results.
- Evaluation of the prognostic significance of altered Mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
- Multi-Institutional Validation of the Predictive Value of KI-67 in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract.
- Spectrum of diverse genomic alterations define non-clear cell Renal carcinoma subtypes.
- Oncologic outcomes following surgical resection of Renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter...
- Validation of mammalian target of rapamycin biomarker panel in patients with clear cell Renal cell carcinoma.
- Degree of Hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract.
- Risk stratification of pubertal children and postpubertal adolescents with clinical stage I Testicular nonseminomatous germ cell tumors.
- Is Extended Lymphadenectomy of Beneficial Therapeutic Value for T2 Urothelial? Cancer.
- Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a revie...
- Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma.
- Dysregulation of beta-catenin is an independent predictor of oncological outcomes in patients with clear cell Renal cell carcinoma.
- A comparison of pediatric, adolescent, and adult Testicular germ cell malignancy.
- Prospective comparison of molecular signatures in urothelial cancer of the Bladder and the upper urinary tract: is there evidence for discordant biology?
- Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy.
- Ki-67 is an independent predictor of oncological outcomes in patients with high-grade upper tract urothelial carcinoma: results of a prospective analysis and a review ...
- Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma.
- Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell Renal cell carcinoma.
- Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy.
- Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy.
- Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary Bladder: can post-induction random Bladder biopsies be avoided?
- Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma.
- Re: A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
- Preoperative pulmonary embolism does not predict poor postsurgical outcomes in RCC patients with venous thrombus.
- Lymphovascular invasion in clear cell renal cell carcinoma-Association with disease-free and Cancer-specific survival.
- Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma.
- Effect of Testicular Germ Cell Tumor Therapy on Renal Function.
- Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma.
- BAP1 loss defines a new class of Renal cell carcinoma.
- A validated tumorgraft model reveals activity of dovitinib against Renal cell carcinoma.
- Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers.
- Clinical nodal staging scores for Bladder cancer: a proposal for preoperative risk assessment.
- Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy.
- Upregulation of TRAG3 gene in urothelial carcinoma of the Bladder.
- Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of Bladder.
- Prognostic effect of urinary Bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma.
- The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper Urinary tract urothelial carcinoma.
- Upper Urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration.
- Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive Bladder cancer.
- Assessment of Hematuria.
- Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
- The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary Bladder.
- pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the Bladder.
- Penile Cancer: management of regional lymphatic drainage.
- Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients.
- Role of fluorescence in situ hybridization in Bladder cancer surveillance of patients with negative cytology.
- Association of angiogenesis related markers with Bladder cancer outcomes and other molecular markers.
- Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
- Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive Bladder cancer.
- Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients.
- Survivin as a prognostic marker for urothelial carcinoma of the Bladder: a multicenter external validation study.
- Comparison of tissue oxygenation profiles using 3 different methods of vascular control during porcine partial nephrectomy.
- p53 predictive value for pT1-2 N0 Disease at radical cystectomy.
- Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 Bladder cancer.
- Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
- Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.
- Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary Bladder cancer.
- The screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing Chronic kidney disease in patients treated for small, u...
- Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial...
- Pseudosarcomatous fibromyxoid tumor of the Bladder.
- Commentary on clinical outcomes of sexuality preserving cystectomy and neoBladder.
- Multiple biomarkers improve prediction of Bladder cancer recurrence and mortality in patients undergoing cystectomy.
- Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the Bladder.
- Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the Bladder.
- Decreased DOC-2/DAB2 expression in urothelial carcinoma of the Bladder.
- Prostate Cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
- The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human Bladder cancer therapy.
- Cooperative effect of cell-cycle regulators expression on Bladder cancer development and biologic aggressiveness.
- Survivin expression is associated with Bladder cancer presence, stage, progression, and mortality.
- Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of Bladder.
- Predictive value of cell cycle biomarkers in nonmuscle invasive Bladder transitional cell carcinoma.
- Ki-67 is an independent predictor of Bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
- Correlation of cyclin D1 and E1 expression with Bladder cancer presence, invasion, progression, and metastasis.
- Outcomes of radical cystectomy for transitional cell carcinoma of the Bladder: a contemporary series from the Bladder Cancer Research Consortium.
- Nomograms provide improved accuracy for predicting survival after radical cystectomy.
- The influence of clinical and pathological stage discrepancy on Cancer specific survival in patients treated for renal cell carcinoma.
- Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the Bladder.
- Should we screen for Bladder cancer in a high-risk population?: A cost per life-year saved analysis.
- Variability in the performance of nuclear matrix protein 22 for the detection of Bladder cancer.
- Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy.
- Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors.
- Economic impact of screening for Bladder cancer using Bladder tumor markers: a decision analysis.
- The diagnosis and treatment of Urethral recurrence after radical cystectomy.
- Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the Bladder compared to transitional cell carcinoma of the Bladder.
- Contemporary techniques and safety of cardiovascular procedures in the surgical management of Renal cell carcinoma with tumor thrombus.
- Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial Bladder cancer.
- Effect of multisite radiofrequency ablation on porcine Renal function.
Schools
Indiana University School of Medicine
Clarian Indiana University Hospital
Procedures Preformed
- AdRenalectomy
- Cystectomy
- Cystourethroscopy and TransUrethral Resection of Bladder Neck
- Destruction or Excision of Vaginal Lesions
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Coventry Health Care
- GEHA
- HealthFirst
- HealthSmart
- Humana
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Old Surety Life Insurance CompanyMedicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
- Whos Who in Medicine and Healthcare
- Fellow (FACS)
Education
-
Indiana University School of Medicine
Hospital
-
University of Texas Southwestern Medical Center -
Children's Health System of Texas -
Veterans Affairs North Texas Health Care System
Drug Facts
| NPI NUMBER | 1720057268 | |
| NPPES Provider LastName | SAGALOWSKY | |
| NPPES Provider FirstName | ARTHUR | |
| NPPES Provider ZIPCode | 753907208 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 168.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720057268 |
| Last Name Of The Provider | SAGALOWSKY |
| First Name Of The Provider | ARTHUR |
| View All |
Similar Doctors
|
|
Dr. Christopher A. Cefalu, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dan B. French, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey C. Toubin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen L. Crotty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ginger B. Isom-Batz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jodi Antonelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aditya Bagrodia, MD |
|
|
Dr. Arthur W. Shannon Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nirmish Singla, MD |